Victor Sandor, MD, is a Non-Executive Director on the Board of Directors of ADC Therapeutics.

Dr. Sandor was most recently Chief Medical Officer at Array BioPharma, Inc. prior to its acquisition by Pfizer Inc. At Array, Dr. Sandor was instrumental in obtaining the approval of Braftovi^® (encorafenib) and Mektovi^® (binimetinib). Prior to joining Array, he was Senior Vice President for Global Clinical Development at Incyte Corporation, where he played a critical role in the approval of Jakafi^® (ruxolitinib). Dr. Sandor was also Vice President and Chief Medical Officer for Oncology at Biogen Idec and held positions of increasing responsibility in oncology product development at AstraZeneca, where he played an important role in the registration of Arimidex^® (anastrozole) for adjuvant use and the development of several early-stage programs through proof of concept.

Dr. Sandor received his M.D.C.M. from McGill University in Montreal, Canada, and completed Fellowship in Medical Oncology at the National Institutes of Health.

Tyrell J. Rivers, PhD, has served as a member of the Board of Directors of ADC Therapeutics since June 2018.

Dr. Rivers is also an Executive Director within AstraZeneca’s Corporate Development group, having responsibility for equity investments, mergers and acquisitions, and divestments. Prior to this role, Dr. Rivers was at MedImmune Ventures, where he specialized in biotechnology investing, and at Merck & Co., Inc. where he led the technical support for multiple commercial vaccine franchises and subsequently directed global business initiatives for accessing key technologies for research and development.

Dr. Rivers earned his BS in Chemical Engineering from the Massachusetts Institute of Technology, a PhD in Chemical Engineering from University of Texas at Austin, and his MBA from the New York University Stern School of Business. Dr. Rivers serves on the Board of Directors for Armaron Bio Ltd, Corvidia Therapeutics, PhaseBio Pharmaceuticals, Inc. and Viela Bio, Inc. and previously G1 Therapeutics, Inc. (GTHX). He also serves as a board observer for several private companies.

Viviane Monges is a Non-Executive Director on the Board of Directors of ADC Therapeutics.

Ms. Monges has more than 30 years of executive-level financial leadership experience with global corporations, predominantly in the pharmaceutical industry. From 2015 to 2017, she served as Chief Financial Officer (CFO) of the Business Excellence Division at Nestlé, S.A. Prior to that, Ms. Monges served as Group CFO at Galderma S.A; EMEA CFO and then Global CFO at the OTC Division of Novartis; CFO of the Europe Region unit and CFO of the Global Pharma Business unit at Wyeth Pharmaceuticals/Pfizer.

Ms. Monges also serves on the Board of Directors of DBV Technologies, Novo Holdings A/S, Voluntis S.A., and Union Chimique Belge Biopharmaceutical Company S.A. (UCB). She served on the board of Idorsia from 2018 to 2021. She holds a B.A. and an M.B.A. in finance and public administration from the École Supérieure de Commerce de Paris.

Dr. Peter Hug brings a wealth of global commercial and leadership experience to the Board of Directors of ADC Therapeutics.

Dr. Hug is a 35-year veteran of Roche, where he held positions of increasing responsibility until his retirement at the end of 2018. Most recently, he served as Head of Roche Pharma EEMEA Region, which comprises Eastern Europe, Russia, Central Asia, Turkey, the Middle East, and Africa. Previously, he was Head of Pharma Region Europe, during which time he led a successful transformation of its European commercial operations. Prior to that, Dr. Hug served as Executive Vice President of Roche Pharma Partnering, a role in which he was responsible for licensing, strategic alliances, and mergers and acquisitions. In earlier management roles within Roche, he was involved with multiple product launches, including hematology and oncology therapies.

Dr. Hug is a graduate of the University of Basel, Switzerland. He is also a Board Member and Vice Chairman of the Swiss Post, and he was President of Interpharma (Swiss Pharma Association) until the end of 2018.

Timothy Coughlin, CPA, joined the Board of Directors in June 2025.

He is the former chief financial officer of Neurocrine Biosciences, Inc., a biopharmaceutical company that received FDA approval for INGREZZA® (valbenazine) and ORILISSA® (elagolix), both of which were discovered and developed during his tenure at Neurocrine from 2002 to 2018.

Mr. Coughlin currently serves on the board of directors of Travere Therapeutics, Inc., and as the chair of the board of directors of aTyr Pharma, Inc., both biotechnology companies. He previously served on the board of directors of Peloton Therapeutics, Inc. prior to its sale to Merck in 2019 and Fate Therapeutics, Inc. from 2013 to 2025, both biotechnology companies.

Prior to joining Neurocrine, he was with Catholic Health Initiatives, a nationwide integrated healthcare delivery system, where he served as vice president, Financial Services. Earlier in his career Mr. Coughlin served as a senior manager in the health sciences practice of Ernst & Young LLP and its predecessors.

Mr. Coughlin holds a master’s degree in international business from San Diego State University and a bachelor’s degree in accounting from Temple University. Mr. Coughlin is a certified public accountant in both California and Pennsylvania.

Jean-Pierre Bizzari, M.D. joined ADC Therapeutics as a Non-Executive Director of our board of directors in June 2022.

He is a member of the scientific advisory board of France’s National Cancer Institute and a board member of the European Organisation of Research and Treatment of Cancer. From 2008 to 2015, Dr. Bizzari served as Executive Vice President, Group Head of Clinical Development Oncology at Celgene Corporation. Prior to that, he held various senior clinical development positions at Sanofi S.A., Aventis and Rhône-Poulenc. In addition to our board of directors, Dr. Bizzari also serves as a member of the boards of directors of Halozyme Therapeutics, Inc., Oxford BioTherapeutics Limited, and Nordic Nanovector ASA, and previously served on the boards of directors of Transgene S.A., Onxeo SA and Compugen Limited. Dr. Bizzari holds an M.D. from Nice Medical School.

Bob Azelby joined the Board of Directors in June 2023. Mr. Azelby is an experienced Chief Executive Officer and veteran board member who has spent over 30 years in the biopharmaceutical industry.

He served as President and Chief Executive Officer of Eliem Therapeutics, Inc., from October 2020 to February 2023. Prior to Eliem, he was the Chief Executive Officer of Alder Biopharmaceuticals, Inc., from June 2018 until it was acquired by H. Lundbeck in 2019. Before joining Alder BioPharmaceuticals, Mr. Azelby was the Chief Commercial Officer of Juno Therapeutics for three years until it was acquired by Celgene Corporation. Prior to Juno, he spent 15 years in commercial roles at Amgen, Inc.

Mr. Azelby serves on the boards of directors of Clovis Oncology, Inc., and Chinook Therapeutics, Inc. Previously, he served on the boards of directors for Eliem Therapeutics, Alder BioPharmaceuticals, Cascadian Therapeutics, Inc., and Immunomedics, Inc. He holds a BA in Economics and Religious Studies from the University of Virginia and an MBA from Harvard Business School.

Ron Squarer is a global biopharmaceutical leader with extensive oncology commercialization expertise.

Mr. Squarer served as Chief Executive Officer and a member of the Board of Directors of Array BioPharma, Inc. from 2012 until 2019, during which time he executed an oncology-focused research, development, and commercialization strategy that culminated in the successful commercial launches of Braftovi^® (encorafenib) and Mektovi^® (binimetinib). During his tenure at Array, the company’s market capitalization grew more than 30-fold, and the company was ultimately acquired by Pfizer Inc. at a total enterprise value of approximately $11.4 billion.

Before joining Array, Mr. Squarer held positions of increasing responsibility with Hospira, Inc., a global pharmaceutical and medical device company. As Senior Vice President and Chief Commercial Officer at Hospira, he was responsible for delivering $4 billion in annual revenue. Mr. Squarer joined Hospira from Mayne Pharma, when it was sold to Hospira in 2007. Before serving as Senior Vice President, Global Corporate and Business Development at Mayne Pharma, Mr. Squarer held leadership roles at both Pfizer (focused on oncology) and SmithKline Beecham Pharmaceuticals (now GlaxoSmithKline) in the US and Europe.

Mr. Squarer currently serves as a member of the Board of Directors of Deciphera Pharmaceuticals, Inc. and Travere Therapeutics, Inc. He earned an MBA from the Kellogg School of Management, Northwestern University, and a Bachelor’s Degree in Biochemistry from the University of California, Berkeley.